N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
from The Medical News http://ift.tt/1w7TjtB
from The Medical News http://ift.tt/1w7TjtB
No comments:
Post a Comment